Press releases

• February 6, 2023 - Regulatory press releaseThe Nomination Committee’s proposal for the election of Board members and Chairman of the Board in BioArctic AB
• February 3, 2023 - Regulatory press releaseInterim Report for the period October – December 2022
• January 30, 2023 - Regulatory press releaseLecanemab receives priority review status in Japan

Archive

Calendar

• April 27, 2023 08:00 CETInterim report January – March 2023
• June 1, 2023Annual General Meeting 2023
• July 12, 2023 08:00 CETHalf-Year report January – July 2023
• November 8, 2023 08:00 CETInterim report January – September 2023

Read more

Full Year Report 2022

BioArctic published the company’s Full Year Report for the period January –December 2022 on Friday, February 3, 2023, at 08:00 a.m. CET.

• Report
• Presentation
• Webcast

Read the report

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more